Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

KemPharm to Present at the 2nd Annual Neuroscience Biopartnering and Investment Forum

GlobeNewswire March 27, 2017

KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting

GlobeNewswire March 16, 2017

KemPharm, Inc. Reports Fourth Quarter and Year End 2016 Results

GlobeNewswire March 9, 2017

KemPharm, Inc. to Report Fourth Quarter and Year End 2016 Results

GlobeNewswire February 28, 2017

KemPharm Announces Additional Patent Protection for Prodrug Portfolio

GlobeNewswire February 23, 2017

KemPharm to Present at Upcoming Investor Conferences

GlobeNewswire February 7, 2017

SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of KemPharm, Inc. and Advises Investors with Losses to Contact the Firm

Business Wire February 3, 2017

Lifshitz & Miller LLP Announces Investigation of Dr. Reddy's Laboratories Limited, Exterran Corporation, Gigamon Inc., KemPharm, Inc., Navient Corporation, NCI, Inc., Opus Bank, PixarBio Corporation and Yahoo! Inc.

PR Newswire February 3, 2017

CRITICAL INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire January 27, 2017

Shareholder Alert: Lundin Law PC Announces an Investigation of KemPharm, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire January 23, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of KemPharm, Inc. - KMPH

PR Newswire January 23, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of KemPharm, Inc. (KMPH)

PR Newswire January 23, 2017

KEMPHARM NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Significant Losses Investing In KemPharm, Inc. To Contact The Firm

PR Newswire January 20, 2017

Robbins Arroyo LLP: KemPharm, Inc. (KMPH) Misled Shareholders According to a Recently Filed Class Action

Business Wire January 20, 2017

KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain

GlobeNewswire January 9, 2017

KemPharm to Present at Biotech Showcase 2017

GlobeNewswire January 4, 2017

KemPharm Granted "Fast Track" Designation for KP201/IR

GlobeNewswire December 20, 2016

KemPharm’s KP415, An Investigational Prodrug of D-Methylphenidate, Completes Phase 1 Proof-of-Concept Trial for the Treatment of ADHD

GlobeNewswire December 14, 2016

CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup

Benzinga.com  November 29, 2016

KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain

GlobeNewswire November 29, 2016